trending Market Intelligence /marketintelligence/en/news-insights/trending/ylua0o9mMBJ01M8fgt4xOA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Oncolytics raising $3.7M via sale of common shares to fund research

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Oncolytics raising $3.7M via sale of common shares to fund research

Oncolytics Biotech Inc. plans to raise $3.7 million in gross proceeds through an underwritten public offering of 4,619,773 common shares and warrants at a combined price of 81 cents apiece.

The warrants, which carry an exercise price of 90 cents each, will be issued separately and can be used to buy an additional 4,619,773 common shares. They will expire five years after issuance.

Calgary, Alberta-based Oncolytics gave the underwriter an option to buy up to an additional 692,965 common shares or warrants at the same price.

Net proceeds from the offering, which is expected to close by Aug. 16, will be used for research and working capital purposes, the cancer drug developer said.

Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager for the offering.